| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022386157 |
| P356 | DOI | 10.1046/J.1523-1755.2002.00424.X |
| P698 | PubMed publication ID | 12081593 |
| P5875 | ResearchGate publication ID | 11292864 |
| P2093 | author name string | Maureen A McBride | |
| Sundaram Hariharan | |||
| Wida S Cherikh | |||
| Christopher P Johnson | |||
| Barbara A Bresnahan | |||
| Christine B Tolleris | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 311-318 | |
| P577 | publication date | 2002-07-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Post-transplant renal function in the first year predicts long-term kidney transplant survival | |
| P478 | volume | 62 |
| Q38615283 | A Machine Learning Approach Using Survival Statistics to Predict Graft Survival in Kidney Transplant Recipients: A Multicenter Cohort Study |
| Q42878989 | A clinical scoring system highly predictive of long-term kidney graft survival |
| Q87268775 | A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients |
| Q51749415 | A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. |
| Q31041909 | A joint model for longitudinal and time-to-event data to better assess the specific role of donor and recipient factors on long-term kidney transplantation outcomes |
| Q42724173 | A new clinical prediction tool for 5-year kidney transplant outcome |
| Q46651476 | A retrospective study of the prognostic impact of cytokine secretion in mixed lymphocyte culture on long-term graft function following allogeneic renal transplantation |
| Q35214584 | Abnormal glucose metabolism and metabolic syndrome in non-diabetic kidney transplant recipients early after transplantation |
| Q46808789 | Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression |
| Q57175190 | Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial |
| Q33865743 | An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies |
| Q49493713 | Analysis of biomarkers within the initial 2 years posttransplant and 5-year kidney transplant outcomes: results from Clinical Trials in Organ Transplantation-17. |
| Q48170563 | Anastomosis time as risk factor for kidney transplant outcome: more pieces to the puzzle |
| Q24240164 | Antihypertensive treatment for kidney transplant recipients |
| Q89860779 | Application of Artificial Intelligence Techniques to Predict Survival in Kidney Transplantation: A Review |
| Q46873854 | Basiliximab (Simulect) in acute tubular necrosis high-risk kidney transplantation |
| Q49643119 | Being Thoughtful about Desensitization |
| Q38064538 | Belatacept utilization recommendations: an expert position |
| Q56897769 | Belatacept: a novel immunosuppressive agent for kidney transplant recipients |
| Q35975390 | Beneficial Effect of Moderate Exercise in Kidney of Rat after Chronic Consumption of Cola Drinks |
| Q37781355 | Biological agents in kidney transplantation: belatacept is entering the field |
| Q33584895 | Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial |
| Q53546683 | C4d deposition is associated with immune cells infiltrating in kidney allograft glomerulitis and peritubular capillaritis. |
| Q50939129 | CT-based renal volume and graft function after living-donor kidney transplantation: Is there a volume threshold to avoid? |
| Q48156702 | Cadaveric kidney transplantation: five years experience at a single center |
| Q36155850 | Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials |
| Q37811508 | Can the early elimination of calcineurin inhibitors result in clinical benefits? |
| Q26771406 | Cardiovascular risk factors following renal transplant |
| Q44512344 | Cardiovascular risk factors in diabetic patients with renal transplants. |
| Q44989301 | Caspase inhibition prevents the increase in caspase-3, -2, -8 and -9 activity and apoptosis in the cold ischemic mouse kidney |
| Q46468543 | Change in serum creatinine levels between 6 and 12 months and kidney graft survival: influence of proteinuria |
| Q48329345 | Changing pattern of mortality in renal transplant recipients: a single-center, 30-year experience |
| Q54132116 | Chapter 3 Demographic and biochemistry profile of kidney transplant recipients in the UK in 2010: national and centre-specific analyses. |
| Q51956722 | Chronic kidney disease in renal transplant recipients. |
| Q35985673 | Chronic kidney disease stage progression in liver transplant recipients |
| Q35788053 | Clinical Significance of Pre-Transplant Arterial Stiffness and the Impact of Kidney Transplantation on Arterial Stiffness |
| Q44241283 | Clinical everolimus experience in pediatric renal transplant patients |
| Q51348024 | Clinical significance of proteinuria at posttransplant year 1 in kidney transplantation. |
| Q51060326 | Comparison of glomerular filtration rate measurements with two plasma and single plasma sample methods in renal transplant cases with stable renal graft functions. |
| Q50699634 | Complement Dependence of Murine Costimulatory Blockade-Resistant Cellular Cardiac Allograft Rejection. |
| Q43254675 | Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study |
| Q44899008 | Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile |
| Q46512854 | Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. |
| Q80166772 | Correlation of change in serum creatinine levels 30 days after renal transplantation with long-term graft survival |
| Q37958349 | Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation |
| Q35711141 | Cyclosporine renal dysfunction |
| Q51267068 | Cystatin C and albuminuria as predictors of long-term allograft outcomes in kidney transplant recipients. |
| Q54439828 | Cystatin C and serum creatinine as predictors of kidney graft outcome. |
| Q45100299 | De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. |
| Q82591479 | De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients |
| Q46403947 | Deceased-donor kidney transplantation: improvement in long-term survival |
| Q44419285 | Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation1,2 |
| Q40224042 | Decreasing Estimated Glomerular Filtration Rate Is Associated With Increased Risk of Hospitalization After Kidney Transplantation |
| Q26824506 | Delayed graft function in the kidney transplant |
| Q43730119 | Delayed graft function: risk factors, consequences and parameters affecting outcome-results from MOST, A Multinational Observational Study |
| Q61946036 | Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant |
| Q58599467 | Development and validation of a prognostic model for kidney function 1 year after combined pancreas and kidney transplantation using pre-transplant donor and recipient variables |
| Q39366092 | Differential Characteristics of Kidney Transplant Recipients According to 1-Year Chronic Kidney Disease Stage 3a and Stage 3b Graft Function |
| Q33636818 | Disparities in kidney transplant outcomes: a review |
| Q36585295 | Disparities in solid organ transplantation for ethnic minorities: facts and solutions |
| Q42211166 | Does the KDIGO CKD risk stratification based on GFR and proteinuria predict kidney graft failure? |
| Q48585615 | Donation and Transplantation of Kidneys Harvested From Deceased Donors Over the Age of 60 Years in the Upper Silesia Region. |
| Q53552403 | Donor kidney volume and outcomes following live donor kidney transplantation. |
| Q46105895 | Duration of delayed graft function is an important predictor of 1-year serum creatinine |
| Q37346593 | Early Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study |
| Q88070846 | Early and Long-Term Outcomes of Kidney Grafts Procured From Multiple-Organ Donors and Kidney-Only Donors |
| Q34377668 | Early changes in scores of chronic damage on transplant kidney protocol biopsies reflect donor characteristics, but not future graft function |
| Q43984395 | Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation |
| Q52936174 | Early postoperative C-terminal agrin fragment (CAF) serum levels predict graft loss and proteinuria in renal transplant recipients. |
| Q45219603 | Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor long-term graft survival |
| Q40847329 | Early renal function recovery and long-term graft survival in kidney transplantation |
| Q51101954 | Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. |
| Q46323523 | Effect of UMOD genotype on long-term graft survival after kidney transplantation in patients treated with cyclosporine-based therapy. |
| Q44577517 | Effect of early graft function on patient survival in renal transplantation |
| Q80942354 | Effect of posttransplant anti-HLA antibody on outcome of renal transplantation |
| Q90462251 | Effectiveness of Maintenance Immunosuppression Therapies in a Matched-Pair Analysis Cohort of 16 Years of Renal Transplant in the Brazilian National Health System |
| Q40818294 | Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant |
| Q56908066 | Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study |
| Q37033275 | Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results |
| Q54334382 | Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. |
| Q44482864 | Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients |
| Q79348695 | Erythropoietin treatment in the sixth posttransplant month as a prognostic factor for renal allograft survival |
| Q43254721 | Estimated glomerular filtration rate evolution between 6 and 24 months predicts long-term kidney transplant survival among patients with inferior graft function |
| Q35819414 | Estimating glomerular filtration rate in kidney transplantation: Still searching for the best marker |
| Q37290783 | Ethnic advantages in kidney transplant outcomes: the Hispanic Paradox at work? |
| Q46918130 | Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK. |
| Q47100464 | Evaluation of the efficacy and safety of endovascular management for transplant renal artery stenosis |
| Q34546358 | Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies |
| Q35177426 | Evolution of endpoints for renal transplant outcome |
| Q46873832 | Evolution of the renal function is a better predictor of long-term survival than serum creatinine. |
| Q46449559 | Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure |
| Q53574152 | Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients. |
| Q89365886 | Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis |
| Q92543207 | Factors Affecting eGFR Slope of Renal Transplant Patients During the First 2 Years |
| Q39059608 | Factors affecting eGFR 5-year post-deceased donor renal transplant: analysis and predictive model |
| Q26825480 | Factors influencing long-term outcome after kidney transplantation |
| Q46732475 | Factors related to long-term renal transplant function in children |
| Q53518646 | Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial. |
| Q37450234 | First year renal function as a predictor of kidney allograft outcome |
| Q51502463 | First-year renal function predicts long-term renal allograft loss. |
| Q80275342 | Fractional creatinine clearance of the donated kidney using Cockcroft-Gault formula as a predictor of graft function after living donor transplantation |
| Q35711546 | From cyclosporine to the future |
| Q44608644 | Gingival overgrowth in kidney transplant recipients treated with cyclosporine and its relationship with chronic graft nephropathy |
| Q44323496 | Glutathione S-transferase M1 gene polymorphism is associated with susceptibility to impaired long-term allograft outcomes in renal transplant recipients |
| Q33779071 | Graft Function and Intermediate-Term Outcomes of Kidney Transplants Improved in the Last Decade: Analysis of the United States Kidney Transplant Database |
| Q90704604 | Has the Expansion in Extended Criteria Deceased Donors Led to a Different Type of Delayed Graft Function and Poorer Outcomes? |
| Q36304550 | High Serum Level of β2-Microglobulin in Late Posttransplant Period Predicts Subsequent Decline in Kidney Allograft Function: A Preliminary Study |
| Q51960438 | High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. |
| Q41699696 | High-grade proteinuria as a cardiovascular risk factor in renal transplant recipients |
| Q37535280 | Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function |
| Q39511353 | Identification of patients at risk for renal impairment after living donor kidney transplantation |
| Q40593752 | Identification of subgroups by risk of graft failure after paediatric renal transplantation: application of survival tree models on the ESPN/ERA-EDTA Registry. |
| Q33959646 | Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods |
| Q38429887 | Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival |
| Q90242262 | Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients |
| Q40508719 | Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation. |
| Q44763454 | Impact of donor dopamine on immediate graft function after kidney transplantation |
| Q47212150 | Impact of low-level BK polyomavirus viremia on intermediate-term renal allograft function. |
| Q52889226 | Impact of surgeon experience on complication rates and functional outcomes of 484 deceased donor renal transplants: a single-centre retrospective study. |
| Q40816172 | Impact of the new fast track kidney allocation scheme for declined kidneys in the United Kingdom |
| Q85930804 | Impaired kidney allograft: how long can it function? A single-center study of the transplantation population |
| Q43271632 | Impaired renal function is associated with mortality in kidney-transplanted patients |
| Q43506390 | Importance of early adequate exposure to cyclosporine in renal transplant outcome: study of 1-year creatinine |
| Q85245399 | Influence of early graft function after renal transplantation and its impact on long-term graft and patient survival |
| Q44608620 | Influence of hypercholesterolemia and acute graft rejection on chronic nephropathy development in renal transplant recipients. |
| Q46386610 | Influence of kidney function to the impact of acute rejection on long-term kidney transplant survival |
| Q51002006 | Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study. |
| Q92120508 | Investigation of the Factors Affecting Allograft Kidney Functions: Results of 10 Years |
| Q37332700 | Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors? |
| Q51296979 | Is renal allograft dysfunction a risk factor for severe infection in kidney transplant recipients? |
| Q48183274 | Lack of Impact of Hyperchloremia in Brain-Dead Organ Donors on the Onset of Kidney Allograft Function in the Recipients |
| Q38626279 | Laparoscopic Sleeve Gastrectomy Improves Renal Transplant Candidacy and Post-Transplant Outcomes in Morbidly Obese Patients. |
| Q38391225 | Laparoscopic Transplantation Following Transvaginal Insertion of the Kidney: Description of Technique and Outcome |
| Q46070728 | Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment. |
| Q42078849 | Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation |
| Q35995643 | Live Donor Renal Anatomic Asymmetry and Posttransplant Renal Function |
| Q41189455 | Living-donor and Deceased-donor Renal Transplantation: Differences in Early Outcome--A Single-center Experience |
| Q42612170 | Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up |
| Q33871255 | Long-term graft function changes in kidney transplant recipients |
| Q35827268 | Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus |
| Q44525017 | Long-term outcome of deceased donor renal transplants correlates with the 30-day creatinine reduction ratio |
| Q42795561 | Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy |
| Q46526992 | MDRD-estimated GFR at one year post-renal transplant is a predictor of long-term graft function |
| Q37639626 | Measuring vs estimating glomerular filtration rate in kidney transplantation. |
| Q45058860 | Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. |
| Q64252507 | Metabolomics Approaches for the Diagnosis and Understanding of Kidney Diseases |
| Q42375665 | Micophenolat Mofetil versus Azathioprine: effects on renal graft function in early posttransplant period. |
| Q35773561 | Micro-MR imaging-based computational biomechanics demonstrates reduction in cortical and trabecular bone strength after renal transplantation |
| Q35125766 | Minimizing calcineurin inhibitor drugs in renal transplantation |
| Q92557691 | Modeling Long-Term Graft Survival With Time-Varying Covariate Effects: An Application to a Single Kidney Transplant Centre in Johannesburg, South Africa |
| Q38089948 | Molecular monitoring for rejection and graft outcome in kidney transplantation |
| Q34005059 | Molecular pathogenesis of post-transplant acute kidney injury: assessment of whole-genome mRNA and miRNA profiles |
| Q64945718 | Molecular profile of urine extracellular vesicles from normo-functional kidneys reveal minimal differences between living and deceased donors. |
| Q86546093 | Monocyte implication in renal allograft dysfunction |
| Q36010496 | Mortality Prediction after the First Year of Kidney Transplantation: An Observational Study on Two European Cohorts |
| Q92101243 | Mortality and Morbidity in Kidney Transplant Recipients With a Failing Graft: A Matched Cohort Study |
| Q42010223 | N-Octanoyl dopamine transiently inhibits T cell proliferation via G1 cell-cycle arrest and inhibition of redox-dependent transcription factors |
| Q52148155 | N-octanoyl dopamine treatment exerts renoprotective properties in acute kidney injury but not in renal allograft recipients. |
| Q58796854 | Negative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year Post-Transplantation: Can it Be Changed by Modifying Immunosuppression? |
| Q37322729 | Neutrophil gelatinase-associated lipocalin in kidney transplantation is an early marker of graft dysfunction and is associated with one-year renal function. |
| Q39220325 | Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients |
| Q33630998 | Old habits die hard; does early urinary catheter removal affect kidney size, bacteriuria and UTI after renal transplantation? |
| Q34312520 | On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. |
| Q46966000 | One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. |
| Q44707783 | One-year posttransplant renal function is a strong predictor of long-term kidney function: results from the Neoral-MOST Observational Study |
| Q42418219 | Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients. |
| Q43299413 | Optimizing immunosuppression with sirolimus in the first year posttransplantation: experience in the United States |
| Q44812426 | Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys |
| Q80958118 | Our experiences in kidney transplantation and monitoring of kidney graft outcomes |
| Q35168067 | Outcomes in kidney transplantation |
| Q37149431 | Pathogenesis and management of chronic allograft nephropathy |
| Q33522450 | Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study |
| Q35745307 | Perceived discrimination predicts longer time to be accepted for kidney transplant |
| Q34020514 | Periodontitis case definition affects the association with renal function in kidney transplant recipients |
| Q91636318 | Perirenal Adipose Tissue Displays an Age-Dependent Inflammatory Signature Associated With Early Graft Dysfunction of Marginal Kidney Transplants |
| Q44608227 | Peritubular capillaritis in early renal allograft dysfunction is an indicator of acute rejection |
| Q44989307 | Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation |
| Q35995894 | Plasma ADMA associates with all-cause mortality in renal transplant recipients |
| Q44663038 | Poor predictive value of serum creatinine for renal allograft loss |
| Q51789761 | Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. |
| Q35810035 | Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. |
| Q37994851 | Pre- and post-transplant care: nursing management of the renal transplant recipient: part 2. |
| Q46442971 | Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients |
| Q38612834 | Pre-transplant histology does not improve prediction of 5-year kidney allograft outcomes above and beyond clinical parameters |
| Q47656083 | Precision Transplant Medicine: Biomarkers to the Rescue |
| Q31056244 | Predicting Individual Renal Allograft Outcomes Using Risk Models with 1-Year Surveillance Biopsy and Alloantibody Data. |
| Q44481997 | Predicting kidney graft failure using time-dependent renal function covariates |
| Q40591571 | Predicting long-term kidney graft survival: can new trials be performed?1,2 |
| Q86067712 | Predicting long-term outcome in renal transplantation |
| Q44976426 | Prediction of renal allograft function with early Doppler ultrasonography |
| Q38829547 | Prediction, prevention, and management of delayed graft function: where are we now? |
| Q89450780 | Predictive Factors for Improved Renal Function in Renal Transplantation Recipients |
| Q43544029 | Predictive factors in chronic allograft nephropathy |
| Q28182098 | Predictive value of urinary retinol binding protein for graft dysfunction after kidney transplantation |
| Q51981967 | Predictors of chronic allograft nephropathy from protocol biopsies using histological and immunohistochemical techniques. |
| Q45034693 | Preservation of graft function in low-risk living kidney transplant recipients treated with a combination of sirolimus and cyclosporine |
| Q46843936 | Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients |
| Q51532707 | Prevalence and progression of chronic kidney disease after renal transplantation. |
| Q37723175 | Prevalence and risk factors for early chronic allograft nephropathy in a live related renal transplant program |
| Q43284027 | Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival |
| Q44976388 | Pushing the envelope in renal preservation; improved results with novel perfusate modifications for pulsatile machine perfusion of cadaver kidneys |
| Q54505605 | Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. |
| Q44419259 | Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1 |
| Q53459320 | Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. |
| Q28080994 | Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes |
| Q42722902 | Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants |
| Q91611032 | Relationship between early proteinuria and long term outcome of kidney transplanted patients from different decades of donor age |
| Q63681840 | Renal Function, Albuminuria, and the Risk of Cardiovascular Events After Kidney Transplantation |
| Q46582074 | Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation |
| Q51467286 | Renal function following living, standard criteria deceased and expanded criteria deceased donor kidney transplantation: impact on graft failure and death. |
| Q46986732 | Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine |
| Q56908171 | Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant |
| Q51923633 | Renal transplantation in dialysis patients with the history of coronary artery bypass grafting and cardiac valve replacement. |
| Q90595520 | Results of Transplantation of Kidneys Procured From Donors After Brain Death Aged 60 Years and Older |
| Q53463705 | Revised Arterial Anastomosis for Improving Murine Kidney Transplant Outcomes. |
| Q30275826 | Risk Factors for Graft Loss in Pediatric Renal Transplant Recipients After Transfer of Care |
| Q45958511 | Risk factors for graft dysfunction in the late period of renal transplantation. |
| Q36479764 | Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study |
| Q95334549 | Risk for Delayed Graft Function in Deceased Donor Renal Transplant Patients: A Single-Center Experience From North India |
| Q35508196 | Role of Hypertension and Anaemia in Left Ventricular Remodelling in Patient with Renal Allograft in the First Post-transplant Year |
| Q87355722 | Routine determination of GFR in renal transplant recipients by HPLC quantification of plasma iohexol concentrations and comparison with estimated GFR |
| Q26799916 | Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients |
| Q40507842 | Serum uromodulin predicts graft failure in renal transplant recipients |
| Q44545351 | Serum β2-microglobulin at discharge predicts mortality and graft loss following kidney transplantation |
| Q45100303 | Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation |
| Q56908156 | Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids |
| Q46452764 | Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients. |
| Q45171038 | Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival |
| Q44899016 | Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years |
| Q42654342 | Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients |
| Q36082082 | Sirolimus: a new option in transplantation |
| Q38716798 | Standardized and weighted time-dependent receiver operating characteristic curves to evaluate the intrinsic prognostic capacities of a marker by taking into account confounding factors |
| Q45100323 | Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation |
| Q35841386 | Strategies to prevent chronic allograft nephropathy in kidney transplantation: focus on calcineurin inhibitors |
| Q44935481 | Surrogate markers for long-term renal allograft survival |
| Q38866277 | Surveillance biopsies after paediatric kidney transplantation: A review |
| Q30909793 | Survival of renal transplant patients: data from a tertiary care center in Turkey |
| Q34639752 | Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study |
| Q44770921 | Systolic blood pressure diurnal variation is not a predictor of renal target organ damage in kidney transplant recipients |
| Q46690549 | Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure |
| Q50211007 | Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil |
| Q41250271 | The Kidney Transplant Morbidity Index (KTMI): a simple prognostic tool to help determine outcome risk in kidney transplant candidates |
| Q54962211 | The Kinetics of Anti-HLA Antibodies in the First Year after Kidney Transplantation: In Whom and When Should They Be Monitored? |
| Q64891366 | The Last Year Before Graft Failure Negatively Impacts Economic Outcomes and is Associated With Greater Healthcare Resource Utilization Compared With Previous Years in the United Kingdom: Results of a Retrospective Observational Study. |
| Q27319529 | The Natural History of Kidney Graft Cortical Microcirculation Determined by Real-Time Contrast-Enhanced Sonography (RT-CES) |
| Q89782890 | The Preliminary Results of Bortezomib Used as A Primary Treatment for An Early Acute Antibody-Mediated Rejection after Kidney Transplantation-A Single-Center Case Series |
| Q40410816 | The effect of anastomosis time on outcome in recipients of kidneys donated after brain death: a cohort study |
| Q42601096 | The effect of cross-reactive epitope group matching on allocation and sensitization |
| Q36992544 | The financial impact of immunosuppressant expenses on new kidney transplant recipients |
| Q44816562 | The first year renal function as a predictor of long-term graft survival after kidney transplantation |
| Q42375654 | The influence of renal alograft function on cardiovscular status and left ventricular remodelling |
| Q88091943 | The minimal-access kidney transplantation technique in living-donor transplantation: results from a retrospective analysis |
| Q41828910 | The predictive value of kidney allograft baseline biopsies for long-term graft survival |
| Q39409549 | The rate of decline of glomerular filtration rate is a predictor of long-term graft outcome after kidney transplantation. |
| Q44339735 | The relationship between donor age and cadaveric renal allograft survival is modified by the recipient's blood pressure |
| Q38063962 | The role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents |
| Q94560419 | The safety, immunological benefits, and efficacy of ginseng in organ transplantation |
| Q46007205 | Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. |
| Q47863864 | Tubular maximum phosphate reabsorption capacity in living kidney donors is independently associated with one-year recipient GFR. |
| Q44812438 | Two decades of experience with cyclosporine in renal transplantation in Helsinki |
| Q41177320 | Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome |
| Q43421536 | Understanding Trends in Kidney Function 1 Year after Kidney Transplant in the United States |
| Q40964596 | Urinary biomarkers of chronic allograft nephropathy. |
| Q34525420 | Urinary calprotectin and posttransplant renal allograft injury. |
| Q36640019 | Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival |
| Q79819453 | Use of cyclosporine in renal transplantation |
| Q92377644 | Validation of the Kidney Donor Profile Index (KDPI) to assess a deceased donor's kidneys' outcome in a European cohort |
| Q36223638 | Variability of the Estimated Glomerular Filtration Rate in the First Year after Kidney Transplantation Is an Independent Risk Factor for Poor Renal Allograft Outcomes: A Retrospective Cohort Study. |
| Q90595567 | Very Long-term Survival of the Transplanted Kidney-Characteristics of Recipients |
| Q36796584 | Vitamin D status and outcomes after renal transplantation. |
| Q55080670 | What is the impact of human leukocyte antigen mismatching on graft survival and mortality in renal transplantation? A meta-analysis of 23 cohort studies involving 486,608 recipients. |
| Q44595688 | Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus.1 |
| Q36155832 | Workshop on late renal allograft dysfunction |
| Q82564710 | [Immunosuppressor treatment in kidney transplantation from a live donor] |
| Q37218125 | mToR inhibitors-induced proteinuria: mechanisms, significance, and management |
Search more.